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Angiogenesis requires endothelial cell survival and pro-
liferation, which depend upon cytokine stimulation
together with integrin-mediated cell adhesion to
extracellular matrix; however, the question of which
speci¢c integrins are the best targets for suppressing
neovascularization is controversial and unresolved.
Therefore, we designed experiments to compare contri-
butions of individual integrins from both the av and b1
integrin subfamilies. With immobilized antibodies, we
determined that adhesion through integrins a1b1, a2b1,
avb3, and avb5 each individually supported dermal mi-
crovascular endothelial cell survival. Also, substratum
coated with collagen I (which binds a1b1 and a2b1) and
vitronectin (which binds avb3 and avb5) each supported
survival. Importantly, substratum coated with combi-
nations of collagen I and vitronectin were most e¡ective
at promoting survival, and survival on three-dimen-
sional collagen I gels was strongly enhanced by vitro-
nectin. Vascular endothelial growth factor activation of
the p44/p42 mitogen-activated protein kinase pathway,
which is required for angiogenesis, was supported
by adhesion through either a1b1, a2b1, avb3, or avb5, and
pharmacologic inhibition of this pathway blocked pro-
liferation and suppressed survival. Therefore, these stu-
dies establish that the a1b1, a2b1, avb3, and avb5 integrins
each support dermal microvascular endothelial cell via-
bility, and that each collaborate with vascular endothe-
lial growth factor to support robust activation of the
mitogen-activated protein kinase pathway which med-
iates both proliferation and survival. Moreover, survival
is supported most signi¢cantly by extracellular ma-
trices, which engage all of these integrins in combina-
tion. Consistent with important complementary and
overlapping functions, combined antagonism of these
integrins provided superior inhibition of angiogenesis
in skin, indicating that multiplicity of integrin involve-
ment should be considered in designing strategies for
controlling neovascularization. Key words: neovasculari-
zation/VEGF/integrins/endothelial. J Invest Dermatol 120:
1100 ^1109, 2003
V
ascular endothelial growth factor (VEGF) is a potent
angiogenic cytokine essential for the angiogenesis
associated with normal embryonic development,
wound healing, and cancer (Dvorak et al, 1995;
Ferrara, 1995). VEGF promotes angiogenesis by sti-
mulating endothelial cell survival, proliferation, and migration
(Ferrara and Henzel, 1989; Alon et al, 1995; Ferrara, 1995). In addi-
tion,VEGF selectively regulates endothelial cell gene expression;
and through its action as a potent vascular permeability factor,
VEGF rapidly promotes extravasation of plasma proteins from
postcapillary venules (Senger, 2001). Extravasated plasma proteins
include the adhesive proteins vitronectin and ¢bronectin (Senger,
1996), and also ¢brinogen, which is rapidly converted to insolu-
ble, cross-linked ¢brin (Dvorak et al, 1985, 1995).Thus, through its
action as a vascular permeability factor,VEGF rapidly transforms
the matrix of the extravascular compartment. In the absence of
microvascular hyperpermeability, collagens are generally the
most abundant components of interstitial matrix. For example,
collagens account for approximately 75% of the dry weight of
skin, and most of this is type I (Weinstein and Boucek, 1960).
Therefore, during VEGF-driven neovascularization of skin, en-
dothelial cells must colonize a matrix consisting of collagen I,
combined with plasma-derived vitronectin, ¢bronectin, and ¢-
brinogen that extravasate as a consequence of VEGF-induced
permeability. Remarkably,VEGF selectively increases interactions
between dermal microvascular endothelial cells and this complex
provisional matrix by selectively inducing expression of the cell
surface integrins a1b1, a2b1, and avb3 (Senger et al, 1996, 1997).
These three integrins are members of a large family of heterodi-
meric transmembrane adhesion receptors, most of which bind
components of extracellular matrix (Hynes, 1992; Ruoslahti et al,
1994). The a1b1 and a2b1 integrins bind collagens and laminin-1
(Elices and Hemler, 1989; Languino et al, 1989; Ignatius et al, 1990;
Santoro and Zutter, 1995; Gardner et al, 1996), and the avb3 integ-
rin binds the arginine^glycine^aspartate (RGD) cell binding mo-
tif found in vitronectin, ¢bronectin, and ¢brin (Cheresh, 1991;
Hynes, 1992; Ruoslahti et al, 1994). Thus, VEGF both transforms
the composition of the interstitial matrix and also enhances en-
dothelial cell interactions with this matrix by inducing expres-
sion of speci¢c integrins. In addition, VEGF stimulates integrin
adhesive function at the cell surface through internal endothelial
cell signaling pathways (Byzova et al, 2000); and, conversely, the
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avb3 integrin supports activation of VEGF receptor-2 (Soldi et al,
1999). Thus, much evidence indicates that regulation of endothe-
lial cell adhesion is central to the biology of VEGF. Studies both
with integrin antagonists (Brooks et al, 1994a; Eliceiri and
Cheresh, 1999) and integrin null mice (Hynes and Bader, 1997;
Hynes et al, 1999) have indicated that integrins are important for
angiogenesis. Most attention has focused on members of the av
integrin subfamily (Brooks et al, 1994b, 1995; Drake et al, 1995;
Friedlander et al, 1996; Bader et al, 1998; Eliceiri and Cheresh,
1999); however, b1 subfamily integrins are also important (Bloch
et al, 1997; Drake et al, 1992; Senger et al, 1997, 2002; Kim et al,
2000; Taverna and Hynes, 2001).We previously demonstrated that
combined antagonism of the a1b1 and a2b1 integrins markedly
suppressed VEGF-driven angiogenesis in mouse skin, indicating
functional signi¢cance for these VEGF-induced integrins in sup-
porting angiogenesis (Senger et al, 1997). In addition, others found
that antagonism of integrin avb3 suppressed angiogenesis in a
variety of animal models (Brooks et al, 1994b, 1995) and that an-
tagonism of a closely related integrin, avb5 preferentially inhib-
ited VEGF-driven angiogenesis (Friedlander et al, 1995). Thus,
integrins a1b1, a2b1, avb3, and avb5 all have been implicated func-
tionally in angiogenesis. Moreover, as outlined above, integrins
a1b1, a2b1, and avb3 are selectively induced by VEGF; and extra-
cellular matrix protein ligands for all of these integrins are
present in relative abundance at sites of VEGF-driven
neovascularization. Cell migration, survival, and proliferation
in vitro are all dependent on integrin-mediated adhesion to extra-
cellular matrix (Akiyama et al, 1989; Wary et al, 1996; Meredith
and Schwartz, 1997; Giancotti and Ruoslahti, 1999; Assoian and
Schwartz, 2001; Schwartz, 2001), and therefore the dependence
of angiogenesis on integrin function is not surprising; however,
the importance of av integrin subfamily members to angiogen-
esis has not been compared directly with the importance of b1
integrin subfamily members for angiogenesis; and, consequently,
the relative importance of these integrins to angiogenesis has re-
mained unresolved and controversial (Carmeliet, 2002; Reynolds
et al, 2002). In particular, the possibility that integrins from di¡er-
ent subfamilies serve key overlapping and/or complementary
functions has not been examined previously, and the possibility
that combined antagonism of multiple integrin subfamilies pro-
vides maximal inhibition of angiogenesis has not been consid-
ered. Therefore, because integrins a1b1, a2b1, avb3, and avb5 all
have been implicated inVEGF-driven angiogenesis, we designed
experiments to compare these integrins individually in support-
ing key microvascular endothelial cell functions. Furthermore, in
a mouse model of VEGF-driven skin neovascularization, we
tested the hypothesis that combined antagonism of a1b1, a2b1,
and av integrins provides optimal inhibition of angiogenesis.
MATERIALS AND METHODS
VEGF, endothelial cells, and cell culture Puri¢ed recombinant
human VEGF165, expressed in Sf21 cells, was obtained from the NCI
Preclinical Repository, Biological Resources Branch (Frederick, MD).
Human dermal microvascular endothelial cells were isolated from
neonatal foreskins and cultured as previously described (Richard et al,
1998). All experiments were performed with cells at the fourth to seventh
passage. Approval for working with human tissue was granted by the
Institutional Review Board of the Beth Israel Deaconess Medical Center.
Cell survival assays with immobilized integrin monoclonal
antibodies (MoAb) EIA binding plates (96 well, Costar, Cambridge,
MA) were coated with 25 mg goat anti-mouse IgG per ml, Fc-speci¢c
(Sigma, St Louis, MO) for 3 h at 371C, and remaining protein binding
sites were blocked with 10 mg per ml heat-denatured (651C, 1 h) bovine
serum albumin (BSA) (Sigma, low endotoxin, no. A9306) for 4 h. Next,
integrin and control MoAb at 10 mg per ml were added at 371C for 2 h.
Antibodies included the following: avb3 (clone LM609), avb5 (clone
P1F6), and a1 (clone FB12) all from Chemicon International (Temicula,
CA); a2 (clone A2-IIE10 from Upstate Biotechnology, Lake Placid, NY);
a1 (clone AGF1.3) and a2 (clone26G8) A.R.deF. and V.E.K.; and ¢nally
isotype IgG1 control MoAb (clones G192-1, and 107.3) from Pharmingen
(La Jolla, CA). The di¡erent isotype control antibodies were
indistinguishable in these assays as were the two di¡erent a1 MoAb and
the two di¡erent a2 MoAb. In all cases, wells were washed twice with
phosphate-bu¡ered saline (PBS) before use to remove unbound material.
In preparation for these experiments, con£uent microvascular endothelial
cells at passage 6 or less were incubated for 72 h in EBM-2 (Clonetics,
San Diego, CA) with 2% fetal bovine serum and 20 ng VEGF per ml.
This protocol for VEGF stimulation induces expression of integrins a1b1,
a2b1, and avb3 (Senger et al, 1996, 1997). For assay, cells were gently
trypsinized, washed twice in serum-free EBM-2, and suspended at
1.5105 cells per ml in serum-free medium (EBM-2 with 1 mg per ml
BSA and insulin-transferrin-selenium growth media supplement G from
Life Technologies, Gaithersburg, MD) (Meredith et al, 1993). One hundred
microliters of cell suspension was loaded into each well; VEGF (20 ng per
ml) and PD98059 (25 mM, Calbiochem, San Diego, CA) (Alessi et al, 1995)
were added where indicated. After 22 h at 371C in a standard tissue culture
incubator, survival was measured with an established method involving the
£uorescent calcein AM substrate (Molecular Probes, Eugene, OR)
(Decherchi et al, 1997; Gatti et al, 1998). One hundred microliters of 4 mM
calcein AM substrate in Dulbecco’s PBS was added to each well and
incubated with cells at 371C for 30 min, and read on a SLT Spectra£uor
£uorescent plate reader at 485 nm (excitation) and 535 nm (emission).
Signal ampli¢cation was standardized among plates. All experiments were
repeated at least three times with similar results. Statistical analyses were
performed with the two-sided unpaired t test (InStat Program).
Cell survival assays with collagen I/vitronectin matrices Two
experimental strategies were employed. First, 96 well tissue culture plates
were coated for 1 h at room temperature with collagen I and/or
vitronectin (both from BD Biosciences, Bedford, MA) at the indicated
concentrations. Remaining protein binding sites were blocked by
incubating with 1 mg per ml heat-denatured BSA for 1 h at 371C. Plates
were washed twice with PBS. Fifty microliters of a cell suspension
containing 10,000 cells per ml in serum-free medium were added to each
well.VEGF (20 ng per ml) was included where indicated. Cell survival was
measured at 24 h with calcein AM as described above. In addition,
experiments were performed with three-dimensional matrices prepared as
follows. Acid-solubilized collagen I (BD Biosciences) at 41C was
neutralized according to manufacturer’s instructions and diluted in cold
serum-free medium to a ¢nal concentration of 1 mg per ml. The
neutralized collagen was added to 24 well tissue culture plates (250 ml per
well) and incubated at 371C. The collagen I polymerized into a rigid gel
typically within 20 min or less. Where indicated, vitronectin at the
indicated concentrations was mixed with the liquid collagen I before
polymerization. Two hundred and ¢fty microliters of a suspension
containing 100,000 cells per ml in serum-free medium was applied to the
collagen I and collagen I/vitronectin three-dimensional matrices. To
determine integrin involvement in mediating cell survival on three-
dimensional matrices, the same integrin-blocking MoAb used as agonists
in the immobilized MoAb experiments described above, were employed
as antagonists here by including them in soluble form together with the
cell suspension at a concentration of 10 mg per ml. Survival was measured
at 24 h as described above.
Analyses of p44/p42 mitogen activated protein kinases
(MAPK) Experiments were performed in Costar 96 well EIA plates
coated ¢rst overnight with 10 mg per ml Fc-speci¢c goat anti-mouse IgG
(Sigma), followed by blocking of remaining nonspeci¢c protein binding
sites with 100 mg per ml BSA (fraction V, Sigma no. A9306) for 2 h at
371C, followed by incubation for 1 h with 10 mg mouse MoAb per ml.
Mouse MoAb included the following: avb3 (clone LM609), avb5 (clone
P1F6), and a1 (clone FB12); all from Chemicon International; and a2
(clone A2-IIE10 from Upstate Biotechnology). Following incubation with
MoAb, wells were washed three times with PBS. Dermal microvascular
endothelial cells were gently trypsinized, and washed twice in serum-free
EBM-2, and 8104 cells in serum-free medium were added to antibody-
coated wells. Cells were allowed to attach and spread, and following decay
of MAPK activity to baseline (4 h), cells were stimulated with 20 ngVEGF
per ml. At harvest, the entire contents of each well was lysed in standard
sodium dodecyl sulfate sample bu¡er (Laemmli, 1970) without reducing
agents but containing protease and phosphatase inhibitors: 1 mM AEBSF,
1 mM aprotinin, 20 mM leupeptin, 35 mM bestatin, 15 mM pepstatin A, and
15 mM E-64 (all from Sigma), and 1 mM ethylenediamine tetraacetic acid,
1 mM ethyleneglycol-bis-(b-aminoethylether)-N,N,N0,N0-tetraacetic acid,
2.5 mM sodium pyrophosphate, 5 mM sodium orthovanadate, and 50 mM
sodium £uoride. One half the total volume of each sample was
electrophoresed under reducing conditions on standard Laemmli gels
containing 10% (w/v) polyacrylamide followed by electrophoretic transfer
to Transblot membranes (Biorad, Richmond, CA). Blots were blocked for
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1 h with 5% (w/v) nonfat dry milk and stained with phospho-MAPK
(Erk1/2) rabbit polyclonal antibody (New England Biolabs, Beverly, MA)
and subsequently with total Erk1 rabbit polyclonal antibody (K-23,
Santa Cruz Biotechnology, Santa Cruz, CA). Bound primary antibody
was detected by staining with horseradish peroxidase-conjugated goat
anti-rabbit IgG (New England Biolabs) followed by visualization
with chemiluminescence (Renaissance from NEN, Boston, MA). All
experiments were repeated at least three times with similar results.
Thymidine incorporation assays Costar 24 well tissue culture plates
were coated with 10 mg per ml collagen I or vitronectin in PBS for 2 h at
371C. Next, remaining protein binding sites were blocked by incubating
with 100 mg per ml BSA in PBS overnight at 371C. Dermal
microvascular endothelial cells (2.5104) were plated in serum-free
medium (see Survival assays with integrin MoAb above) containing 1 mCi
per ml tritiated thymidine (90 Ci per mmol). Where indicated,
proliferation was stimulated by adding VEGF to a ¢nal concentration of
20 ng per ml. Also, where indicated, the MAPK kinase (MEK 1)
inhibitor PD98059 (Alessi et al, 1995) was added to a ¢nal concentration of
25 mM. After 24 h, incorporation of radiolabeled thymidine was measured
as described previously (Smith et al, 1999). Experiments were repeated at
least three times with similar results.
Induction of angiogenesis in mouse skin, integrin antagonism with
MoAb and peptidomimetic S247, and analyses of angiogenesis The
skin angiogenesis assay was based on a previously described model
(Passaniti et al, 1992) with the following modi¢cations. All animal studies
were approved by our Institutional Animal Care and Use Committee.
Athymic NCr nude mice (females, 25 g, 8 wk old) were injected
subcutaneously midway on the right and left back sides with 0.25 ml
growth factor-reduced Matrigel (BD Biosciences, Billerica, MA) at a ¢nal
concentration of 9 mg per ml together with 1.0106 SK-MEL-2 cells
transfected for stable expression of human VEGF165. Soon after injection,
the Matrigel implant solidi¢ed and persisted without apparent deterio-
ration throughout the 6 d assay interval. Following injection of Matrigel,
the animals were divided into ¢ve groups of eight animals each. Groups
were injected intraperitoneally with antibodies and av integrin antagonist
as follows: (a) 150 mg blocking hamster anti-mouse a1 MoAb (clone Ha 31/
8) together with 150 mg blocking hamster anti-mouse a2 MoAb (clone Ha
1/29) (Mendrick et al, 1995) on days 1, 3, and 5; (b) 300 mg of isotype-
matched control hamster MoAb (clone Ha 4/8) on days 1, 3, and 5; (c) 1.25
mg (¼ 50 mg per kg) av integrin antagonist S247 (Meyer et al, 2001) (see
below) every 12 h; (d) saline vehicle control for S247 every 12 h; and (e) av
integrin antagonist S247 in combination with blocking a1 MoAb and
blocking a2 MoAb with each being administered according to the same
respective MoAb and S247 schedules employed in groups (a) and (c).
The av integrin antagonist used in these experiments, S247 ((3S)-3-
(3 -bromo-5-chloro-2-hydroxyphenyl)-3 -{[N-({5-[(5-hydroxy-1,4,5,6 -
tetrahydropyrimidin-2-yl)amino]pyridin-3 -yl}carbonyl)glycyl]amino}
propanoic acid), is a small molecule peptidomimetic and highly selective
inhibitor of av integrins (Meyer et al, 2001). As determined with puri¢ed
avb3 binding to vitronectin in a solid-phase receptor binding assay in vitro,
the IC50 for this compound is 0.18 nM. In cell-based assays (Westlin et al,
2001) S247 inhibits avb3 binding to vitronectin with an IC50 of 0.4 nM.
Additionally, as determined with cell-based assays, S247 inhibits cell
adhesion dependent on either avb5 (IC50¼1.5 nM) or avb1 (IC50¼
1.6 nM). By contrast, S247 is greater than three orders of magnitude
selective for integrin avb3 in comparison with integrin aIIbb3 and inhibits
vitronectin binding to aIIbb3 only at relatively high concentrations (IC50
244 nM). After 6 d, the animals in all treatment groups were killed and
dissected. Implants together with associated skin were ¢xed for 3 h in
10% bu¡ered formalin and embedded in para⁄n. Sections were cut,
depara⁄nized, and treated with 0.1% trypsin for 30 min at 371C to
enhance antigen availability prior to staining with 2 mg per ml rat anti-
mouse CD31 MoAb (clone MEC 13.3, Pharmingen). Bound antibody was
stained with secondary rabbit anti-rat antibody coupled to horseradish
peroxidase (Vectastain Elite Kit, Vector Laboratories, Burlingame, CA)
and visualized with liquid DAB-Plus substrate (Zymed, San Francisco,
CA). Sections were counterstained with hematoxylin (Vector
Laboratories). NIH Image Program 1.61 was used to measure average
blood vessel diameters from representative digitized images obtained from
eight specimens per group (total vessel number 4100 per group).
Combined blood vessel cross-sectional areas at the Matrigel/host interface,
determined as a percent of the total tissue, were measured from
representative digitized images obtained from 410 specimens of each
group, also using NIH Image (n¼ 30 for each group). Statistical analyses
were performed with the two-sided unpaired t test (InStat Program).
RESULTS
Dermal microvascular endothelial cell survival is supported
by anchorage individually through a1b1, a2b1, avb3, and
avb5 integrins Because angiogenesis is ultimately dependent
upon endothelial cell survival, we began by investigating
speci¢c integrin involvement in supporting viability of dermal
microvascular endothelial cells in vitro. Human dermal
microvascular endothelial cells have been reported previously to
express the integrins a1b1, a2b1, avb3, or avb5 (De¢lippi et al, 1991;
Swerlick et al, 1992b; Xu et al, 1994; Senger et al, 1997); and we
con¢rmed that the cells used in this study also expressed these
integrins with £uorescence-activated cell sorter analyses (data
not shown). To measure survival supported by endothelial cell
anchorage through each integrin individually, microtiter wells
were coated with speci¢c integrin MoAb as described in
Materials and Methods. Although in solution these MoAb
function as speci¢c antagonists by sterically blocking integrin
attachment to their natural ligands of extracellular matrix, these
same MoAb, when immobilized to plastic substratum, serve as
speci¢c ligands that support cell attachment and spreading
(Holmes and Engvall, 1993). As shown in Fig 1, endothelial cell
anchorage through each of these integrins individually supported
endothelial cell survival signi¢cantly in comparison with
substratum coated with isotype control MoAb or BSA, which
did not support cell attachment.
Although precise quantitative interpretation of these
experiments is limited by the possibility that the integrin MoAb
employed do not exactly mimic natural ligands in supporting
endothelial cell survival, several observations are worthy of
mention. For example, inclusion of VEGF enhanced survival
particularly for cells anchored through MoAb directed against
integrins a1b1 or a2b1 (po0.04 and po0.0003, respectively)
suggesting the possibility of special cooperativity between these
collagen-binding integrins and VEGF. Moreover, immobilized
a2b1 MoAb was the most e¡ective in supporting survival, and
anchorage through a1b1 MoAb in combination with a2b1 MoAb
provided little increase above a2b1 MoAb alone. Similarly,
endothelial cell anchorage through avb3 and avb5 MoAb in
combination did not increase survival above that observed in
Figure1. Survival of microvascular endothelial cells anchored spe-
ci¢cally through av and/or b1 integrins. Cells were applied in serum-
free medium (720 ng per ml VEGF) to microtiter wells coated with spe-
ci¢c integrin MoAb as indicated (see Materials and Methods), and percentage
survival (7SD) was determined after 24 h. Endothelial cell attachment
through each integrin MoAb individually supported survival signi¢cantly
in comparison with either BSA alone or control isotype MoAb (for each,
pp0.0004, which is considered extremely signi¢cant).
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cells anchored through either avb3 or avb5 MoAb individu-
ally; however, survival of VEGF-stimulated endothelial cells
anchored through a1b1, a2b1, avb3, and avb5 in combination was
increased more than 100% in comparison with survival of
endothelial cells anchored through avb3 and avb5. Nevertheless,
and regardless of the signi¢cance of quantitative di¡erences
observed with the di¡erent integrin MoAb, these experiments
indicate that integrins a1b1, a2b1, avb3, and avb5 each indi-
vidually support endothelial cell survival.
Anchorage through collagen I and vitronectin in
combination supports dermal microvascular endothelial
cell survival signi¢cantly more than either collagen I or
vitronectin individually The functional importance of the
a1b1/a2b1 and avb3/avb5 integrins in supporting endothelial cell
survival, as determined above with immobilized MoAb, was
corroborated independently in parallel experiments involving
substratum coated with collagen I, which is a natural ligand for
integrins a1b1 and a2b1 (Elices and Hemler, 1989; Ignatius et al,
1990; Santoro and Zutter, 1995; Gardner et al, 1996), and
vitronectin, which is a natural ligand for integrins avb3 and
avb5 (Smith et al, 1990; Wayner et al, 1991; Swerlick et al, 1992a).
These experiments indicated that endothelial cell adhesion
to either collagen I or vitronectin both strongly support
endothelial cell survival (Fig 2a). Interestingly, in ¢ve separate
experiments collagen I-coated plastic supported survival better
than vitronectin-coated plastic, consistent with our ¢ndings
with immobilized integrin MoAb (Fig 1) indicating that
endothelial cell adhesion through integrins a1b1 and a2b1
supported survival better than adhesion through avb3 and avb5.
Most importantly, in these same experiments (Fig 2a) we found
that endothelial cell survival was signi¢cantly enhanced when
cells were attached to substratum coated with a combination of
collagen I and vitronectin, either in the absence or presence of
VEGF (po0.003). Thus, these experiments indicated that an
extracellular matrix capable of ligating integrins a1b1, a2b1, avb3,
and avb5 supports endothelial cell survival better than either
collagen I or vitronectin alone. In particular, they suggested that
the a1b1/a2b1 and the avb3/avb5 integrins serve complementary
functions in supporting endothelial cell survival. Although the
classical approaches for investigating integrin functions in vitro
typically involve immobilized MoAb or matrix proteins as
described above, three-dimensional matrices are encountered by
cells in vivo. Therefore, we also examined survival of dermal
microvascular endothelial cells on three-dimensional collagen I
matrix. In marked contrast to plastic coated with collagen I,
which supported460% endothelial cell survival for 24 h in the
presence of VEGF (Fig 2a), three-dimensional collagen I
supported endothelial cell survival by less than 30% (Fig 2b).
This ¢nding is consistent with previous reports that long-term
survival of endothelial cells is compromised in three-dimen-
sional collagen I (Ilan et al, 1998), and it illustrates important
di¡erences between the classical assays for investigating matrix
protein function (e.g., with matrix protein-coated plastic) and
assays involving three-dimensional matrices that better imitate
matrix protein structure in vivo. Importantly, when an equal
concentration of vitronectin was added to the collagen I gels,
survival was improved nearly 3-fold both in the absence and
presence of VEGF. Also, when employed at 30% and 60%
the concentration of collagen I, vitronectin was most e¡ective
at promoting survival when VEGF was included, and the
data suggested a similar trend in the absence of VEGF
(Fig 2b). Regardless, these experiments established that dermal
microvascular endothelial cell survival on three-dimensional
collagen I is enhanced E 300% by inclusion of an equal
concentration of vitronectin, either in the presence or absence of
VEGF.
To de¢ne the importance of integrins a1b1 and a2b1 (collagen
receptors) in comparison with integrins avb3 and avb5
(vitronectin receptors) in supporting dermal microvascular
endothelial cell survival on three-dimensional matrices consist-
ing of collagen I and vitronectin in combination, we performed
parallel experiments that included soluble blocking integrin
MoAb. As shown in Fig 2(c), combined inhibition of either
a1b1 and a2b1 or avb3 and avb5 inhibited survival on this mixed
three-dimensional matrix. In the absence of VEGF, both integrin
subfamilies were similarly important, and inhibition of all four
integrins in combination provided greatest inhibition. In the
Figure 2. Anchorage to matrices consisting of collagen I together
with vitronectin supports dermal microvascular endothelial cell
survival signi¢cantly more than either collagen I or vitronectin in-
dividually. Similar to experiments described in Fig 1, cells were applied in
serum-free medium with and without VEGF, as indicated, and survival
(7SD) was measured after 24 h. (a) Survival of cells in wells coated with
combinations of collagen I (a natural ligand for integrins a1b1 and a2b1)
and vitronectin (a natural ligand for integrins avb3 and avb5) supported
survival more signi¢cantly than either collagen I alone or vitronectin alone
(po0.02; four separate experiments). x-axis¼ collagen I and vitronectin
coating concentrations. (b) Survival of cells on three-dimensional matrices
consisting of collagen I (1 mg per ml) in combination with vitronectin at
the concentrations indicated. Note that equal concentrations of vitronectin
and collagen I (1 mg per ml each) supported survival E3-fold more than
collagen I alone, as observed in two separate experiments. (c) Addition of
soluble blocking integrin MoAb to cells plated on a three-dimensional ma-
trix consisting of collagen I and vitronectin (1 mg per ml each) established
that inhibition of the a1b1, a2b1, avb3, and avb5 in integrins in combination
provided the greatest inhibition of survival (po0.03; two separate experi-
ments). Similar to the experiments of (b), which were performed in the
absence of MoAb, survival in the presence of control MoAb was:
(^) VEGF¼ 50%77% and (þ ) VEGF¼ 76%75%.
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presence of VEGF, survival was most dependent on integrins a1b1
and a2b1, consistent with the experiments described in
Fig 1. Nonetheless, inhibition of integrins avb3 and avb5 also
inhibited survival; and, most importantly, inhibition of integrins
a1b1, a2b1, avb3, and avb5 in combination provided the greatest
inhibition of survival (po0.03).
Integrins a1b1, a2b1, avb3, and avb5 each individually support
VEGF activation of p44/p42 MAPK VEGF activates the
p44/p42 (Erk1/Erk2) MAPK signal transduction pathway in
endothelial cells (Parenti et al, 1998; Smith et al, 1999), and this
pathway is critical for cell proliferation (Seger and Krebs, 1995;
Vinals and Pouyssegur, 1999; Roovers and Assoian, 2000;
Assoian and Schwartz, 2001) and angiogenesis (Eliceiri et al,
1998). Moreover, cell anchorage is important for e⁄cient MAPK
activation by cytokines (Short et al, 1998; Aplin et al, 1999). The
individual contributions of a1b1, a2b1, avb3, and avb5 in
supporting MAPK activation by VEGF in microvascular
endothelial cells, however, has not been compared previously.
Therefore, we designed experiments to investigate whether
dermal microvascular endothelial cell attachment through each
of these integrins individually supports MAPK activation by
VEGF. As determined by immunoblotting and staining with
phospho-speci¢c MAPK antibody, VEGF-induced MAPK
activation was detectable but poor in nonadherent cells plated
on plastic coated with BSA or isotype control antibody;
however, VEGF strongly induced activation of MAPK in cells
anchored through each of the integrin antibodies (Fig 3a).
Densitometry indicated that activation was most robust in
endothelial cells anchored through integrins a1b1 and avb3
(Fig 3b). Activation in endothelial cells anchored through
integrins a2b1 or avb5 was less intense, but it was strong in
comparison with cells plated on substratum coated with BSA or
isotype control antibody. Therefore, these experiments indicate
that microvascular endothelial cell attachment through integrins
a1b1, a2b1, avb3, or avb5 each supports activation of p44/p42
MAPK byVEGF.
VEGF stimulates MAPK-dependent DNA synthesis
similarly in dermal microvascular endothelial cells
anchored to either collagen I or vitronectin As described
above, the integrins a1b1 and a2b1 are receptors for collagen I,
and the avb3 and avb5 integrins are receptors for vitronectin. To
compare collagen I with vitronectin in supporting proliferation
of dermal microvascular endothelial cells, we coated plastic
substratum with these matrix proteins individually and blocked
remaining protein binding sites with BSA. Under these
conditions (see Materials and Methods) cells were prevented from
attaching to control substratum during the experimental interval
(24 h). Thus, anchorage to the collagen I-coated wells and to the
vitronectin-coated wells was attributable to collagen I and
vitronectin, respectively. As measured by thymidine incorpora-
tion,VEGF similarly stimulated DNA synthesis in microvascular
endothelial cells on both matrix proteins (Fig 4), indicating that
anchorage through a representative a1b1/a2b1 ligand (collagen I)
and a representative avb3/avb5 ligand (vitronectin) comparably
support proliferation. In contrast,VEGF failed to stimulate DNA
synthesis signi¢cantly in cells plated on control substratum coated
with BSA alone, consistent with an anchorage requirement for
growth. Finally, the MAPK kinase (MEK 1) inhibitor PD98059,
Figure 3. VEGF stimulation of the p44/p42 MAPK pathway is in microvascular endothelial cells is supported by anchorage through either av
or b1 integrins. Cells were applied in serum-free medium to microtiter wells coated with speci¢c integrin MoAb as indicated in Materials and Methods.
After plating, MAPK phosphorylation was allowed to decay for 4 h prior to stimulation with VEGF. (a) As indicated by staining with phospho-speci¢c
MAPK antibody (top), VEGF induced marked activation in cells plated either on a1 MoAb, a2 MoAb, avb3 MoAb, or avb5 MoAb but poorly induced
MAPK activation in cells plated on isotype control MoAb or BSA. Also, failure of VEGF to activate MAPK robustly in cells plated on BSA or control
(Ctl) antibodies in comparison with integrin MoAb was not attributable to anoikis because cell viability remained 490%, as determined by replating of
cells on collagen-coated plastic. To control for sample composition and loading, the blots were stripped and restained with antibody that recognizes both
phosphorylated and nonphosphorylated forms of Erk1 (bottom). (b) Densitometric analyses of p44/p42 MAPK phosphorylation. The blot shown in (a) was
scanned; and relative OD of phospho-MAPKwas adjusted for minor di¡erences in loading, based on signal intensity of total Erk1. Similar results were
obtained consistently in three separate experiments.
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which speci¢cally suppresses the p44/p42 MAPK pathway (Alessi
et al, 1995), inhibited VEGF stimulation of DNA synthesis in
endothelial cells anchored to collagen I or vitronectin (Fig 4),
indicating that this pathway is critical for proliferation of
endothelial cells anchored through either of these matrix
proteins.
Endothelial cell anchorage through a1 MoAb and a2 MoAb
each supported thymidine incorporation signi¢cantly in
comparison with control isotype MoAb; however, incorporation
was onlyE 10% of that observed in cells anchored to collagen I;
and there was no detectable incorporation in cells anchored
through avb3 or avb5 MoAb beyond that observed in cells
plated on control substratum (data not shown). Therefore, we
conclude that, although these immobilized integrin MoAb
strongly support endothelial cell survival and MAPK activation,
they do not mimic the functional activities of natural matrix
protein ligands in supporting proliferation.
The p44/p42 MAPK pathway supports survival of dermal
microvascular endothelial cells anchored through multiple
integrins In addition to cell proliferation, the p44/p42 (Erk1/
Erk2) MAPK pathway has been implicated in cell survival (Ilan
et al, 1998; Le Gall et al, 2000).With the MAPK kinase (MEK 1)
inhibitor PD98059 we tested the importance of this pathway for
survival of VEGF-stimulated cells anchored through the a1b1,
a2b1, avb3, and avb5 integrins, individually and in combination.
This inhibitor most signi¢cantly suppressed survival of
endothelial cells anchored through a2b1, but survival of
endothelial cells anchored through other integrins also was
reduced (Table I). In particular, inhibition of MAPK activity
suppressed survival of endothelial cells anchored through the
combination of a1b1, a2b1, avb3, and avb5 integrins by nearly
50%. Thus, these experiments together with those of Fig 3
illustrate functional linkage between VEGF activation of the
MAPK pathway, microvascular endothelial cell survival, and the
integrins a1b1, a2b1, avb3, and avb5.
Combined antagonism of a1b1, a2b1, and av integrins
provides optimum inhibition of VEGF-driven angiogenesis
in skin Previously, we have shown that antagonism of a1b1 and
a2b1 suppresses angiogenesis (Senger et al, 1997, 2002). Similarly,
others have shown that angiogenesis is inhibited by antagonism
of avb3 and/or avb5 (Brooks et al, 1994a; Drake et al, 1995;
Friedlander et al, 1995, 1996). The in vitro experiments described
above indicate that a1b1, a2b1, avb3, and avb5 each support
critical functions. In particular, these observations predict that
combined antagonism of a1b1, a2b1, avb3, and avb5 should
provide optimum inhibition of VEGF-driven angiogenesis in
comparison with antagonism of subsets of these four integrins.
To test this prediction, we designed experiments to compare
antagonism of a1b1/a2b1 and antagonism of av integrins with
antagonism of all in combination.We employed a mouse model
of skin angiogenesis involving subdermal injection of Matrigel
together with immortalized human cells stably transfected for
expression of human VEGF165. Neither Matrigel alone nor the
untransfected cells in Matrigel provoked angiogenesis in the
overlying skin. In contrast, Matrigel containing VEGF
transfectants potently induced neovascularization. Moreover,
during the experimental interval angiogenesis was con¢ned to
the host dermis and not found signi¢cantly in the Matrigel
implants. Consequently, these experiments examined angio-
genesis in the extracellular matrix of the host. For antagonism
of a1b1 and a2b1, we administered a1-blocking and a2-blocking
hamster MoAb at times and doses previously determined to
provide maximum inhibition of angiogenesis in this model (see
Materials and Methods). Importantly, the blocking MoAb employed
in these experiments do not recognize the respective human
integrins and therefore did not interact with the transfected
human cells expressing VEGF. For inhibition of av integrins, we
employed the synthetic antagonist S247 (Meyer et al, 2001), which
was administered at times and doses found previously to achieve
maximal inhibition. To control for the possibility that S247
might a¡ect survival, proliferation, or VEGF expression by
the transfectants that served as the angiogenic stimulus, the
transfectants were grown for 6 d on Matrigel in vitro in the
presence of 100 mM S247, a dose equivalent to the average
maximal plasma concentration in vivo following intraperitoneal
injection. Neither cell number nor VEGF expression, as
determined with immunoblotting, was a¡ected.
Each test group consisted of eight animals, each with two
Matrigel implants. All animals were harvested on day 6,
and skin overlying the Matrigel implants was dissected and
processed for immunohistochemical analyses. Thus, overlying
skin specimens from a total of 16 implants per group were
Figure 4. VEGF stimulates DNA synthesis similarly in endothelial
cells anchored to either to collagen I or vitronectin. Microvascular
endothelial cells were plated in serum-free medium (720 ng per ml
VEGF) on plastic coated with BSA, vitronectin, or collagen I (see Materials
and Methods).Where indicated, the MEK 1 inhibitor PD98059 was added to
inhibit the p44/p42 MAPK pathway.Thymidine incorporation (7SD) was
measured at 24 h. Note that collagen I and vitronectin supported incor-
poration similarly and thatVEGF enhanced incorporation in cells anchored
through either of these matrix proteins. Also, on both collagen I and vitro-
nectin, incorporation was suppressed by PD98059.
Table I. The p44/p42 MAPK pathway supports survival of
microvascular endothelial cells anchored through multiple
integrinsa
% Survival
Substratum PD 98059 þPD98059
BSA 13.877.4 13.476.3
Control antibody 12.575.1 20.673.7
a1 antibody 40.073.7 34.174.3
a2 antibody 62.773.4 35.273.7
a1 antibodyþ a2 antibody 65.677.0 35.172.9
avb3 antibody 32.973.7 32.475.6
avb5 antibody 38.074.7 26.576.9
av3 antibodyþavb5 antibody 32.674.6 27.173.2
All integrin antibodies 75.475.5 39.271.4
aCells were plated on plastic coated with speci¢c integrin MoAb or BSA or
control isotype MoAb in serum-free medium containing VEGF. Survival
(%7SD) was measured after 24 h. To determine importance of p44/p42 MAPK
activity, parallel experiments were performed with and without the MEK 1 inhi-
bitor PD98059. Note that MAPK inhibition particularly suppressed survival of
cells anchored through a2 MoAb, avb5 MoAb, and combinations of integrin
MoAb.
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Figure 5. Combined antagonism of a1b1, a2b1, and av integrins provides
optimum inhibition of VEGF-driven angiogenesis in vivo as measured by
CD31 antibody staining of sections cut from para⁄n-embedded specimens.
(a) New blood vessels (V) at the interface between: (M) the Matrigel im-
plant containing the angiogenic stimulus, and (D) the overlying dermis
and smooth muscle cell layer are stained for CD31 (brown color). Note that
blood vessel density was most reduced in the a1 antibodyþ a2 antibo-
dyþ av antagonist group (bottom right panel). Scale bar¼ 50 mm. (b) Vas-
cular cross-sectional area as a percent of total area was measured at the
interface between dermis and the angiogenic stimulus (see a), as described
in Materials and Methods. Data are presented as the mean 7SEM; n¼ 30.
Relative to controls, total cross-sectional area of new blood vessels in the
S247 treatment group and the a1 antibodyþ a2 antibody treatment group
were reducedE60% andE65%, respectively (po0.001 for each). Admin-
istration of S247 together with a1 antibody and a2 antibody resulted in sig-
ni¢cantly further inhibition, yielding a E80% reduction of total vascular
area in cross-section (po0.001).
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analyzed, and results were highly consistent within each group.
Figure 5(a) shows representative tissue samples with blood
vessels in cross-section stained with MoAb to CD 31, illustrating
that, as expected, treatment of animals with a1 MoAb and a2
MoAb suppressed angiogenesis as did treatment with the av
integrin antagonist S247. In particular, inhibition was greatest
with a1 MoAb, a2 MoAb, and compound S247 in combination.
Average new blood vessel diameter (7SEM) was reduced by a1
MoAbþ a2 MoAb treatment to 3.5170.14 mm (po0.001) in
comparison with 6.8170.32 mm (control antibody group).
Similarly, the av antagonist S247 reduced average new blood
vessel diameter to 3.4470.12 mm (po0.001) in comparison
with 6.8370.33 mm (saline vehicle control group). S247 in
combination with a1 antibody and a2 antibody reduced new
blood vessel diameter signi¢cantly (po0.001) further to
2.5670.09 mm. Measurement of vascular area as a percent of
tissue area in cross-section (Fig 5b) established that, relative to
controls, total cross-sectional area of new blood vessels in the
S247 treatment group and the a1 antibody and a2 antibody
treatment group were reduced E60% and E65%, respectively
(po0.001 for each). Administration of S247 together with a1
antibody and a2 antibody resulted in signi¢cantly further
inhibition, yielding E80% reduction in total vascular area in
cross-section (po0.001).
DISCUSSION
As outlined at the beginning, previous studies have implicated av
and speci¢c b1 integrins in angiogenesis; however, the possibility
that these distinct integrin subfamilies serve overlapping and
complementary functions has remained unexplored. This funda-
mental gap in understanding has left unanswered the controver-
sial question of which integrins are most critical for angiogenesis.
Therefore, studies described here were designed to compare di-
rectly the importance of av integrins and the a1b1/a2b1 integrins
for angiogenesis in vivo; and to compare the functional signi¢-
cance of these integrins in supporting endothelial cell survival,
endothelial cell proliferation, andVEGF activation of the MAPK
pathway; all of which are required for angiogenesis.
Importantly, experiments described here establish a similar sig-
ni¢cance for the integrins a1b1, a2b1, avb3, and avb5 in supporting
dermal microvascular endothelial cell survival, and they establish
with three-dimensional matrices that survival is best supported
by engagement of all of these integrins in combination. In addi-
tion, these experiments establish that anchorage through each of
these integrins individually supports VEGF activation of the
MAPK pathway, which is critical for endothelial cell proliferation
and contributes importantly to endothelial cell survival. Finally,
we found that combined antagonism of a1b1, a2b1, and av integ-
rins provided optimal inhibition of VEGF-driven angiogenesis
in skin indicating that both of these integrin subfamilies contri-
butes signi¢cantly to neovascularization in vivo. Thus, this study
indicates that the a1b1, a2b1, avb3, and avb5 integrins each parti-
cipate in skin neovascularization through mechanisms that in-
clude support of microvascular endothelial cell survival and
proliferation. In particular, this study illustrates both functional
overlap and complementation among these integrins, and it
demonstrates the importance of considering the multiplicity of
integrin involvement in designing optimal strategies for
controlling angiogenesis.
Consistent with ¢ndings reported here, it has been established
previously that during angiogenesis microvascular endothelial
cells encounter a provisional extracellular matrix that includes ¢-
brin, vitronectin, ¢bronectin, and interstitial collagens (Dvorak et
al, 1995; Senger, 2001). Endothelial cells adhere to these matrix
proteins through multiple integrins including a1b1, a2b1, avb3,
and avb5 (Hynes, 1992; Ruoslahti et al, 1994). Therefore, our ¢nd-
ings that multiple integrins are important for angiogenesis is en-
tirely consistent with the complexity of the extracellular matrix
in which angiogenesis occurs. Moreover, our ¢ndings raise the
possibility that antagonism of integrins in addition to those in-
vestigated here may be required to achieve total inhibition. Such
integrins likely include a5b1, an important ¢bronectin receptor
that has also been implicated in angiogenesis (Hynes et al, 1999;
Kim et al, 2000; Taverna and Hynes, 2001). As indicated above,
¢bronectin is present in the matrix encountered by endothelial
cells during angiogenesis.
It is well established that anchorage through integrins is critical
for cell survival (Meredith et al, 1993; Frisch and Francis, 1994; Re
et al, 1994; Meredith and Schwartz, 1997; Aoudjit and Vuori, 2001;
Bachelder et al, 2001); however, precisely which and how many
integrins are required to satisfy the adhesion requirement for mi-
crovascular endothelial cell survival has not been de¢ned. Our in
vitro experiments indicate that a1b1, a2b1, avb3, and avb5 each in-
dividually support survival of microvascular endothelial cells.
Furthermore, they de¢ne important complementary activity for
the a1b1/a2b1 integrins and the avb3/avb5 integrins in supporting
endothelial cell survival on a three-dimensional matrix consisting
of a mixture of collagen I and vitronectin. Thus, ¢ndings re-
ported indicate that a1b1, a2b1, avb3, and avb5 each individually
support endothelial cell survival but that survival on three-di-
mensional matrix is signi¢cantly improved by combined engage-
ment of these integrins.
Previously, integrins a2b1, a3b1, and a5b1 each had been shown
to support epidermal growth factor activation of p44/p42 (Erk1/
Erk2) MAPK in endothelial cells (Aplin et al, 1999), and integrins
a1b1 and a2b1 had been shown to supportVEGF activation of this
pathway (Senger et al, 2002); however, the activities of individual
av and b1 integrins in supporting activation of p44/p42 MAPK
had not been compared directly. In this study we found that en-
dothelial cell anchorage through integrins a1b1 or avb3 provided
for maximal activation and that integrins a2b1 and avb5 also in-
dividually supported strong activation of this pathway. Thus, the
adhesion requirement for VEGF activation of MAPK in micro-
vascular endothelial cells is well satis¢ed by anchorage through
any one of these four integrins. In addition, we found that VEGF
similarly stimulated DNA synthesis in endothelial cells attached
either to collagen I, which is a natural ligand for integrins a1b1
and a2b1, or to vitronectin, which is a natural ligand for integrins
avb3 and avb5. Furthermore, DNA synthesis in cells attached
either to collagen I or vitronectin was inhibited substantially by
a speci¢c inhibitor of the p44/p42 MAPK pathway. Thus, our
data draw no major distinctions among the av integrins and b1
integrins studied here with regard to their activities in supporting
either VEGF activation of a key signaling pathway required for
proliferation or VEGF stimulation of DNA synthesis. Moreover,
we found no evidence for distinctions between anchorage
through collagen I or vitronectin with regard to the importance
of MAPK activity for DNA synthesis; however, we did observe
interesting di¡erences among speci¢c integrins regarding the re-
quirement of MAPK activity for endothelial cell survival. Viabi-
lity of endothelial cells anchored through integrin a2b1was most
severely a¡ected by MAPK inhibition; and, interestingly, this in-
tegrin was also most active in promoting survival. Nevertheless,
as discussed above, integrins a1b1, avb3, and avb5 also supported
microvascular endothelial cell survival signi¢cantly.
Thus, our in vitro studies identify important functional overlap
among integrins a1b1, a2b1, avb3, and avb5 in satisfying the adhe-
sion requirements for dermal microvascular endothelial cell survi-
val and proliferation and in satisfying the adhesion requirement
for activation of a keyVEGF signaling pathway that is important
for endothelial cell survival, endothelial cell proliferation, and an-
giogenesis. During angiogenesis in vivo, however, such functional
overlap would apply only where ligands for each of these integ-
rins are available. Because ligand speci¢city di¡ers between the
a1b1/a2b1 integrins and the avb3/avb5 integrins, the relative im-
portance of each of these integrins for microvascular endothelial
cell survival and proliferation may di¡er temporally and spatially
during angiogenesis. For example, microvascular endothelial cells
in a collagen-poor matrix consisting primarily of av matrix
protein ligands would likely exhibit strong dependence on av
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integrins. Moreover, av integrins are also probably critical where
collagen degradation is very high, particularly as degradation of
collagen provides exposure of cryptic RGD sequences, which are
bound by av integrins and not normally exposed in native col-
lagen (Davis, 1992). On the other hand, microvascular endothelial
cells residing within a matrix rich in native interstitial collagens
would exhibit strong dependence upon integrins a1b1 and a2b1.
Our ¢ndings reported here indicating that antagonism of the
a1b1/a2b1 integrins or the av integrins separately inhibits angio-
genesis Z60% are consistent with the lack of complete func-
tional overlap in vivo, and they are consistent with the possibility
that important discontinuities or gradients of matrix protein
composition may be encountered by endothelial cells during
neovascularization. These ¢ndings are also entirely consistent
with the complementary activity we identi¢ed for the a1b1,
a2b1, avb3, and avb5 integrins in supporting endothelial cell sur-
vival on three-dimensional matrix consisting of collagen I and
vitronectin. In particular, both the functional overlap and com-
plementation we identi¢ed among integrins a1b1, a2b1, avb3,
and avb5 in the in vitro experiments are consistent with our ¢nd-
ings that combined antagonism of all four integrins provided
superior inhibition of angiogenesis in vivo.
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